Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770063 | 1.00 | CYP2A6 (0.40) | CYP2A6CYP3A4KDM4EALDH1A1 | |
| SCHEMBL726141 | 0.86 | MEN1 (0.39) | CYP2A6ALDH1A1 | |
| SCHEMBL726142 | 0.86 | MEN1 (0.39) | CYP2A6ALDH1A1 | |
| SCHEMBL725885 | 0.83 | ALDH1A1 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL725884 | 0.83 | ALDH1A1 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL1253293 | 0.82 | CYP2A6 (0.51) | CYP2A6CYP3A4 | |
| SCHEMBL1253290 | 0.82 | CYP2A6 (0.51) | CYP2A6CYP3A4 | |
| SCHEMBL726636 | 0.80 | MET (0.36) | KDM4EALDH1A1 | |
| SCHEMBL726635 | 0.80 | MET (0.36) | KDM4EALDH1A1 | |
| SCHEMBL725617 | 0.78 | PLAU (0.42) | CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124633-A1 | Heterocyclic Compounds, Methods of Making Them and Their Use in Therapy | BERMAN JUDD | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124633-A1 | Heterocyclic Compounds, Methods of Making Them and Their Use in Therapy | NQO1, AADAC, SDHA | CYP2A6 820/4885CYP3A4 470/4885KDM4E 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.